Molecular cancer therapeutics
DSP502 combines dual inhibition of PD-L1 and PVR to trigger anti-cancer immune responses.
Vinicio A Melo Gallegos, Shirley Greenwald, Ami Tamir, Lisa J Jacob, Macarena González Corrales, Lior Tsveyer, Alexandra Aronin, Iris Pecker, Rinat Tabakman, Lucy Ghantous, Liat Tamir, Roy Kahn, Elina Zorde Khvalevsky, Amnon Peled, Ori Wald
Published: 202610.1158/1535-7163.MCT-25-0102
Abstract
PD-1 immune checkpoint inhibition (ICI) is ineffective in most cancer patients. However, combination therapy can improve response rates, with the checkpoint TIGIT being a particularly interesting candidate as it is expressed on tumor-infiltrating exh…
Preview only. Read the full abstract at the source